3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      O‐GlcNAcylation promotes colorectal cancer progression by regulating protein stability and potential catcinogenic function of DDX5

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The RNA helicase p68 (DDX5), a key player in RNA metabolism, belongs to the DEAD box family and is involved in the development of colorectal cancer. Here, we found both DDX5 and O‐GlcNAcylation are up‐regulated in colorectal cancer. In addition, DDX5 protein level is significantly positively correlated with the expression of O‐GlcNAcylation. Although it was known DDX5 protein could be regulated by post‐translational modification (PTM), how O‐GlcNAcylation modification regulated of DDX5 remains unclear. Here we show that DDX5 interacts directly with OGT in the SW480 cell line, which is the only known enzyme that catalyses O‐GlcNAcylation in humans. Meanwhile, O‐GlcNAcylation could promote DDX5 protein stability. The OGT‐DDX5 axis affects colorectal cancer progression mainly by regulating activation of the AKT/mTOR signalling pathway. Taken together, these results indicated that OGT‐mediated O‐GlcNAcylation stabilizes DDX5, promoting activation of the AKT/mTOR signalling pathway, thus accelerating colorectal cancer progression. This study not only reveals the novel functional of O‐GlcNAcylation in regulating DDX5, but also reveals the carcinogenic effect of the OGT‐DDX5 axis in colorectal cancer.

          Related collections

          Most cited references33

          • Record: found
          • Abstract: found
          • Article: not found

          Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease.

          O-GlcNAcylation is the addition of β-D-N-acetylglucosamine to serine or threonine residues of nuclear and cytoplasmic proteins. O-linked N-acetylglucosamine (O-GlcNAc) was not discovered until the early 1980s and still remains difficult to detect and quantify. Nonetheless, O-GlcNAc is highly abundant and cycles on proteins with a timescale similar to protein phosphorylation. O-GlcNAc occurs in organisms ranging from some bacteria to protozoans and metazoans, including plants and nematodes up the evolutionary tree to man. O-GlcNAcylation is mostly on nuclear proteins, but it occurs in all intracellular compartments, including mitochondria. Recent glycomic analyses have shown that O-GlcNAcylation has surprisingly extensive cross talk with phosphorylation, where it serves as a nutrient/stress sensor to modulate signaling, transcription, and cytoskeletal functions. Abnormal amounts of O-GlcNAcylation underlie the etiology of insulin resistance and glucose toxicity in diabetes, and this type of modification plays a direct role in neurodegenerative disease. Many oncogenic proteins and tumor suppressor proteins are also regulated by O-GlcNAcylation. Current data justify extensive efforts toward a better understanding of this invisible, yet abundant, modification. As tools for the study of O-GlcNAc become more facile and available, exponential growth in this area of research will eventually take place.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Topography and polypeptide distribution of terminal N-acetylglucosamine residues on the surfaces of intact lymphocytes. Evidence for O-linked GlcNAc.

            Bovine milk galactosyltransferase has been used, in conjunction with UDP-[3H]galactose, as an impermeant probe for accessible GlcNAc residues on the surfaces of lymphocytes. Galactosylation of living thymic lymphocytes is dependent upon cell number, enzyme concentration, UDP-galactose concentration, and Mn2+ concentration. Kinetics of labeling are biphasic, leveling off at approximately 30 min. The data strongly indicate vectorial surface labeling and covalent attachment of galactose. Thymocytes, T-lymphocytes, and B-lymphocytes have approximately 10(6), 3 X 10(6), and 5 X 10(6) galactosylatable sites on their cell surfaces, respectively. Numerous proteins are exogalactosylated that differ quantitatively among the major functional subsets of lymphocytes. Negligible radioactivity is found in lipid. In thymocytes, 49% of the exogalactosylated oligosaccharides are alkali labile, whereas 80 and 90% of that derived from T-lymphocytes and B-lymphocytes can be beta-eliminated, respectively. Sensitivity of the intact proteins or tryptic peptides to the peptide: N-glycosidase also confirms the relative amounts of cell surface, N-linked and O-linked oligosaccharides which are exogalactosylated. Composition, size, and high performance liquid chromatography on two types of high resolution columns establish that the bulk of the exogalactosylated, beta-eliminated oligosaccharides are Gal beta 1-4GlcNAcitol. These data suggest the presence of O-glycosidically linked GlcNAc monosaccharide on many lymphocyte cell-surface proteins. However, additional experiments indicate that the majority of these moieties appear to be cryptic or inside the cell. Thus, these studies not only describe dramatic differences in the amounts and distribution of terminal GlcNAc residues on phenotypically different lymphocyte populations, but they also describe the presence of a novel protein-saccharide linkage, which is present on numerous lymphocyte proteins.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              DEAD-box proteins: the driving forces behind RNA metabolism.

                Bookmark

                Author and article information

                Contributors
                bingxu0107@hotmail.com
                xiexin@nwu.edu.cn
                Journal
                J Cell Mol Med
                J. Cell. Mol. Med
                10.1111/(ISSN)1582-4934
                JCMM
                Journal of Cellular and Molecular Medicine
                John Wiley and Sons Inc. (Hoboken )
                1582-1838
                1582-4934
                28 November 2018
                February 2019
                : 23
                : 2 ( doiID: 10.1111/jcmm.2019.23.issue-2 )
                : 1354-1362
                Affiliations
                [ 1 ] Laboratory of Tissue Engineering, Faculty of Life Science Northwest University Xi’an Shaanxi China
                [ 2 ] State Key Laboratory of Cancer Biology National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, Air Force Medical University (Fourth Military Medical University) Xi’an Shaanxi China
                [ 3 ] College of Computer Science and Technology Jilin University Changchun Jilin China
                [ 4 ] Department of Gastroenterology Second Affiliated Hospital of Xi'an Jiao tong University Xi’an Shaanxi China
                Author notes
                [*] [* ] Correspondence

                Xin Xie, Laboratory of Tissue Engineering, Faculty of Life Science, Northwest University, Xi’an, Shaanxi, China.

                Email: xiexin@ 123456nwu.edu.cn

                and

                Bing Xu, Department of Gastroenterology, Second Affiliated Hospital of Xi'an Jiao tong University, Xi’an, Shaanxi, China.

                Email: bingxu0107@ 123456hotmail.com

                Article
                JCMM14038
                10.1111/jcmm.14038
                6349181
                30484950
                24011de1-bbc8-449e-a514-ef171e7047ce
                © 2018 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 14 August 2018
                : 11 October 2018
                : 26 October 2018
                Page count
                Figures: 4, Tables: 0, Pages: 9, Words: 12590
                Funding
                Funded by: Natural Science Foundation of Jilin Province
                Award ID: No. 20140101194JC
                Award ID: No. 20150101056JC
                Funded by: National Natural Science Foundation of China
                Award ID: No. 61471181
                Award ID: No. 81702966
                Categories
                Original Article
                Original Articles
                Custom metadata
                2.0
                jcmm14038
                February 2019
                Converter:WILEY_ML3GV2_TO_NLMPMC version:5.5.6 mode:remove_FC converted:28.01.2019

                Molecular medicine
                akt,colorectal cancer,ddx5,mtor,o‐glcnacylation
                Molecular medicine
                akt, colorectal cancer, ddx5, mtor, o‐glcnacylation

                Comments

                Comment on this article